Controlling a vancomycin-resistant enterococci outbreak in a Brazilian teaching hospital.

The purpose of this article was to describe a 2.5-year interventional program designed to control the dissemination after a large hospital outbreak of vancomycin-resistant enterococci (VRE) in a tertiary-care university hospital. A VRE working group was designated to work specifically on controlling VRE intrahospital dissemination after the detection of the first VRE infection at in our hospital in June 2007. The intervention consisted in the interruption of new admissions during a period of 15 days and closure of the index case unit, microbiological surveillance of rectal swabs for VRE, cohorting patients and staff, immediate application of contact precautions, and continuous education. From July 2007 to December 2009, 8,692 rectal swabs were cultured for VRE and 321 (3.7%) were positive. An expressive reduction of the detection of new positive rectal swabs cultures was seen during the year 2009 (1.5%) when compared to 2008 (4.2%) and 2007 (7.2%) (p < 0.005). The annual ratio of VRE per 1,000 admissions reduced from 20.3 in 2007 to 10.07 and 3.82 in 2008 and 2009, respectively (p < 0.001). The continuous microbiologic surveillance for VRE and strict and prompt contact precautions for VRE patients were the fundamental aids in the control of VRE.

Clinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and Candida oral colonization.

The objective of this study was to evaluate Candida oral colonization in human immunodeficiency virus (HIV)-infected patients undergoing long-term highly active antiretroviral therapy (ARV). The cross-sectional study included 331 HIV patients, diagnosed from 1983 to 2003. Oral swabs were performed, and Candida species were determined using ID 32C. Isolates were tested for antifungal susceptibility. Clinical and laboratory data were collected to identify the association with Candida colonization. In total, 161 Candida isolates were detected among 147 of the 331 patients (44%), independently of the time when HIV infection was diagnosed. Candida albicans strains represented 137 (85%) of the isolates, and were susceptible to all of the tested antifungal drugs. Among the non-C. albicans strains, six isolates were dose-dependently susceptible to fluconazole, nine to itraconazole, and seven to ketoconazole. The isolation of Candida was significantly higher in patients with virological failure (83/147; p 0.0002) and CD4(+) T-lymphocyte counts <200 cells/mm(3) (30/83; p 0.0003). Recovery of Candida in the oral cavity was independent of protease inhibitor (PI) usage (p 0.60). Colonized patients typically underwent salvage therapy (p 0.003), and had more episodes of opportunistic fungal infections (p 0.046) and malignancies (p 0.004).Oral Candida colonization in patients under ARV therapy was associated with the immunosupressed status of HIV-infected patients, i.e. low number of CD4(+) T-cells per cubic millimetre, failure of ARV therapy (salvage therapy), and higher number of opportunistic infections and malignancies. Despite the fact that PIs have in vitro antifungal activity, the use of this class of antiretroviral agent did not influence the presence of Candida in the oral cavity of AIDS patients.

Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up.

BACKGROUND: Patients undergoing dialysis usually have a poor response to conventional hepatitis B vaccination. AIM: To observe the effects of intradermal hepatitis B (HB) vaccination in a 13-month prospective study of adult patients with end-stage renal failure. The patients were with or without previous hepatitis B vaccination, but all had antibody titres <10 mUI/mL. METHODS: Patients were allotted to two groups: previous hepatitis B virus vaccination and no previous hepatitis B virus vaccination or anti-HBs titres <10 mUI/mL. Patients in both groups received 16 i.d. injections of 0.1 mL of hepatitis B virus vaccine over an eight-week period. Patients had antibody titres assessed before vaccination, 1 month after and every 3 months for a year. Antibody titres >/=10 mUI/mL were considered protective. RESULTS: Seventy patients completed the protocol. Protective titres were elicited in 82% of each group. Age, time under dialysis, diabetes, smoking and body-mass index were not associated with seroconversion. Persistent protective titres >12 months occurred in 27 (58.7%). Adverse events were trivial. CONCLUSION: Intradermal hepatitis B virus vaccination is an alternative in end-stage renal failure.

[Accidental tetanus: clinical and epidemiological profile of inpatients at a university hospital]. / Tétano acidential: análise do perfil clínico e epidemiológico de casos internados em hospital universitário.

INTRODUCTION: Notwithstanding its substantial decline over the last two decades, acquired tetanus is still a serious health problem in most developing countries. Epidemiological transition is often cited as an explanation for this decline, the increase in vaccination coverage of children being the most obvious cause. Few studies have looked carefully at the current epidemiological patterns of acquired tetanus in developing countries. METHODOLOGY: A descriptive, retrospective (series of cases). An acute care 400 - bed university referral hospital situated in a densely populated and highly urbanized area in Southeastern Brazil (Campinas, SP). Patient records the data-base analysed were from the Epidemiological Surveillance Unit of the hospital. RESULTS: In the 57 month period from January 1989 to March 1996 fifty-three patients were admitted with a diagnosis of acquired tetanus. Fifty patients had clinical confirmation, 3 were otherwise diagnosed. Thirty-two (64%) were male and 18 (36%) female. Fourteen (28%) were from rural areas and 36 (72%) from urban. Mean age was 47.6 years, with a median of 49.5. Of the rural patients, 42.85% were under 30 years and 21.42% were over 50, mean age was 36.21 with a median of 34.5. Fewer urban patients were under 30 (13.88%) than over 50 (58.33%), mean age was 52.19 with a median of 54.5. Trismus was the most frequent (92.0%) clinical sign on admittance, followed by abdominal muscular rigidity (84.0%). Treatment measures were uniform and included tetanus immune globulin, antibiotics, surgical debridement of the wound when feasible, diazepan or curare depending on the intensity of spasms. In the second half of the study period, penicillin was replaced by metronidazol. Overall case fatality rate was 20%, in patients that had to receive curare, it was 60%. Hospitalization exceeded 21 days in 56% (28) of the cases, only 10% (5) had a hospital stay of less than 7 days. CONCLUSION: A high proportion of patients were from rural areas, despite an urbanization rate of more than 90%. In the Campinas region there are two different epidemiological patterns of acquired tetanus: a rural pattern, with a higher proportion of younger patients, determined by an inadequate immunization rate and an urban pattern, similar to that found in industrialized countries, with a higher proportion of older patients. RECOMMENDATIONS: There is an obvious need to immunize older individuals in urban areas and young adults in rural areas. The elimination of acquired tetanus will only be achieved with a wider and more intensive adult vaccination program.

Listeriosis and AIDS: case report and literature review.

Listeriosis is a not uncommon infection in humans, usually associated with immunodeficient states and with newborns. However, relatively few cases have been reported in HIV-infected patients. This scarcity of reported cases has aroused interest in the association of listeriosis and AIDS. In this paper we present a case of meningitis and septicemia caused by Listeria monocytogenes in a female patient with AIDS. A review of recent medical literature indicates that association of listeriosis and AIDS may be more common than it seems. Recent research in host-parasite interaction in listerial infection suggests an important role for tumor necrosis factor (TNF) and for integralin, a bacterial protein, in modulating listerial disease in AIDS patients. Inadequate diagnosis may be in part responsible for the scarcity of reports.

The life cycle of Trypanosoma cruzi under axenic conditions.

The complete life cycle of Trypanosoma cruzi under germfree (GF) conditions was achieved. The Reduvidae insects Dipetalogaster maximus, reared under axenic conditions were infected with Trypanosoma cruzi, strain CL, by feeding on GF infected mice. Axenic trypomastigotes from macerated gnotobiotic insects were used to infect GF and conventional (CV) mice by intraperitoneal, ocular, and oral routes. Infection, followed by blood parasitemia, was obtained in almost all the cases. However, Chagas' disease was more severe in GF animals when compared with CV mice.

Tratamiento del cáncer avanzado de la glándula mamaria con mitoxantrona, s-fluorouracilo y ciclofosfamida / Advanced breast cancer treatment with a combination of mitoxantrona, s-fluorouracil and ciclophosfamide

La combinación de mitoxantrona (M), 5-fluorouracilo (F) y ciclofosfamida (C), se administró como tratamiento inicial a 180 pacintes con cáncer avanzado de la glándula mamaria. Este estudio no comparativo se llevó a cabo en 7 diferentes instituciones médicas de Argentina, Brasil y México. Las dosis utilizadas fueron: mitoxantrona 12 mg/m2 i.v. día 1-21; 5-fluorouracilo 500 mg'm2 i.v. días 1-8-21 y ciclofosfamida 500 mg/m2 i.v. día 1-21. Las dosis se modificaron de acuerdo a la toxicidad presentada. En el 37% de los 1026 ciclos se presentó leucopenia <2000/mm3 y trombocitopenia <100,000/mm3 en el 16%. Náusea y vómito se presentaron en 82%, diarrea en el 27% y alopecia en el 74%. Respuesta global se observó en 88 de 147 pacientes valorables (60%); respuesta completa en 32 (21.8%) y respuesta parcial en 56 (38%), nos e observaron cambios en 38 (25.9%) y progresión en 21 (14.3%). La sobrevida promedio en este grupo fue de 25 meses; actualmente continúan con vida y sin evidencia de actividad tumoral, a más de 6 años, 24 (16.3%) de las pacientes. Aparte de la mielosupesión, en su mayoría neutropenia, la combinación MFC generalmente fue efectiva y bien tolerada con una baja incidencia de efectos secundarios. Se concluye que mitoxantrona en combinación con 5-fluorouracilo y ciclofosfamida, contribuyen a prolongar la sobrevida de las enfermas con cáncer mamario avanzado, mejorando la calidad de vida en un número importante de ellas. Se recomienda la combinación de MFC como esquema de priemra línea.